Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.

被引：1
|
作者：
Vasseur, Damien
Jovelet, Cecile
Cozic, Nathalie
Mazieres, Julien
Barlesi, Fabrice
Bennouna, Jaafar
Gervais, Radj
Moreau, Lionel
Berard, Henri
Molinier, Olivier
Moro-Sibilot, Denis
Souquet, Pierre Jean
Amour, Elodie
Morin, Franck
Zalcman, Gerard
Soria, Jean-Charles
Westeel, Virginie
Lacroix, Ludovic
Besse, Benjamin
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8526
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8526
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
    Besse, B.
    Mazieres, J.
    Ribassin-Majed, L.
    Barlesi, F.
    Bennouna, J.
    Gervais, R.
    Moreau, L.
    Berard, H.
    Debieuvre, D.
    Molinier, O.
    Moro-Sibilot, D.
    Souquet, P. J.
    Jacquot, S.
    Petit, L.
    Lena, H.
    Pignon, J. P.
    Lacas, B.
    Morin, F.
    Milleron, B.
    Zalcman, G.
    Soria, J. C.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1078 - 1083
  • [2] ADJUVANT PAZOPANIB OR PLACEBO IN RESECTED STAGE I NSCLC PATIENTS: RESULTS OF THE NSCLC ADJUVANT RANDOMIZED PHASE II TRIAL (IFCT-0703) FROM THE FRENCH COLLABORATIVE INTERGROUP
    Besse, Benjamin
    Mazieres, Julien
    Ribassin-Majed, L.
    Barlesi, Fabrice
    Bennouna, Jaafar
    Gervais, Radj
    Moreau, Lionel
    Berard, Henri
    Debieuvre, Didier
    Molinier, Olivier
    Moro-Sibilot, Denis
    Souquet, Pierre-Jean
    Pignon, Jean-Pierre
    Amour, Elodie
    Celebic, A.
    Morin, Franck
    Milleron, Bernard
    Zalcman, Gerard
    Soria, Jean-Charles
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S301 - S301
  • [3] Adjuvant pazopanib or placebo in resected stage I NSCLC patients: Results of the NSCLC adjuvant randomized phase II trial (IFCT0703) from the French collaborative Intergroup
    Besse, B.
    Mazieres, J.
    Pignon, J. P.
    Bennouna, J.
    Barlesi, F.
    Gervais, R.
    Amour, E.
    Morin, F.
    Zalcman, G.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S9 - S9
  • [4] Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703.
    Besse, Benjamin
    Mazieres, Julien
    Ribassin-Majed, Laureen
    Barlesi, Fabrice
    Bennouna, Jaafar
    Gervais, Radj
    Moreau, Lionel
    Berard, Henri
    Debieuvre, Didier
    Molinier, Oliver
    Moro-Sibilot, Denis
    Souquet, Pierre Jean
    Pignon, Jean-Pierre
    Amour, Elodie
    Celebic, Aljosa
    Morin, Franck
    Milleron, Bernard
    Zalcman, Gerard
    Soria, Jean-Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Adjuvant Aumolertinib in Resected Stage I EGFRMutated NSCLC: Prospectively Evaluating Efficacy in Residual GGN Lesions
    Huang, C. B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S540 - S541
  • [6] Sequential minimal residual disease (MRD) monitoring: Results from the UK Myeloma XI trial
    De Tute, Ruth
    Cairns, David
    Rawstron, Andrew
    Pawlyn, Charlotte
    Davies, Faith
    Jones, John
    Kaiser, Martin
    Hockaday, Anna
    Striha, Alina
    Cook, Gordon
    Russell, Nigel
    Drayson, Mark
    Jenner, Matthew
    Gregory, Walter
    Morgan, Gareth
    Jackson, Graham
    Owen, Roger
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E45 - E46
  • [7] A molecular biomarker targeted approach to adjuvant therapy for resected pancreatic adenocarcinoma: Results of a phase II prospective trial.
    Postlewait, Lauren McLendon
    Ethun, Cecilia G.
    Kooby, David A.
    Sarmiento, Juan
    Staley, Charles A.
    Brutcher, Edith
    Adsay, Volkan
    El-Rayes, Bassel F.
    Maithel, Shishir Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [8] The potential of minimal residual disease (MRD) in guiding adjuvant therapy (AT) decisions in non-small cell lung cancer (NSCLC)
    Lei, Siyu
    Xu, Haiyan
    Yang, Yaning
    Tian, Linyan
    Ma, Ting
    Wang, Yan
    CANCER RESEARCH, 2024, 84 (06)
  • [9] A Prospective Study of SBRT Boost to Residual Disease in Stage III NSCLC: Updated Results
    McGarry, R. C.
    Feddock, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S651 - S651
  • [10] Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC)
    John, Tom
    Grohe, Christian
    Goldman, Jonathan W.
    Kato, Terufumi
    Laktionov, Konstantin K.
    Bonanno, Laura
    Tiseo, Marcello
    Majem, Margarita
    Domine, Manuel, Sr.
    Ahn, Myung-Ju
    Perol, Maurice
    Hartmaier, Ryan
    Robichaux, Jacqulyne
    Bhetariya, Preetida
    Markovets, Aleksandra
    Rukazenkov, Yuri
    Muldoon, Caitlin
    Herbst, Roy S.
    Tsuboi, Masahiro
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345